
    
      This is a multicenter, randomized, double-blind, and placebo-controlled phase 2 study
      evaluating 2 formulations of HP-5000 in subjects with OA of the knee. The study will consist
      of up to 28-day Screening Phase that will include a Washout Period of current prescription
      and over the counter (OTC) analgesics, a 4-week double-blind Treatment Phase, and a 1-week
      safety Follow-up Period.
    
  